Deucravacitinib: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Deucravacitinib appears in the FDA drug-label database. Marketed as SOTYKTU.
- Drug class
- Tyrosine Kinase 2 Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Tyrosine Kinase 2 Inhibitors (as stated on the FDA label)
FDA-approved use
SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for: • the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other potent immunosuppressants. • the treatment of active psoriatic arthritis in adults. ( 1.2 ) 1.1 Plaque Psoriasis SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants. 1.2 Psoriatic Arthritis SOTYKTU is indicated for the treatment of active psoriatic arthritis in adults.
Phase breakdown
Conditions being studied
Recruiting trials involving Deucravacitinib
- A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
- A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
- A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- A Study to Assess Deucravacitinib Safety in Pregnancy
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Correction of Psoriatic T Cell Signatures by Deucravacitinib
- Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
- Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Common questions
Is Deucravacitinib FDA-approved?
Yes, marketed as SOTYKTU.
How many recruiting trials involve Deucravacitinib?
11 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.